A Study to Confirm Safety and Efficacy of BAN2401 in Participants With Early Alzheimer’s Disease (Clarity AD)

Status

Study Description

This study will be conducted to evaluate the efficacy of BAN2401 in participants with early Alzheimer's disease (EAD) by determining the superiority of BAN2401 compared with placebo on the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 18 months of treatment in the Core Study...

Sponsor

Eisai Inc.

Collaborator

Biogen

Learn More

68Ga-PSMA PET/CT in Prostate Cancer

Status

Enrolling by…

Study Description

The objectives of this study are to replicate the safety and efficacy of 68Ga-PSMA PET/CT and as a diagnostic and decision making tool in the management prostate cancer patients...

Sponsor

Sir Mortimer B. Davis - Jewish General Hospital

Collaborator

Sir Mortimer B. Davis - Jewish General Hospital

Learn More

A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer’s Disease (Generation S2)

Status

Recruiting…

Study Description

The purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for the onset of clinical symptoms of AD based on their age, APOE genotype and elevated amyloid...

Sponsor

Novartis Pharmaceuticals

Collaborator

Amgen, Banner Alzheimer's Institute

Learn More

Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer’s Disease (AD)

Status

Recruiting…

Study Description

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of…

Sponsor

Hoffmann-La Roche

Collaborator

Hoffmann-La Roche

Learn More

Safety and Efficacy of TRx0237 in Subjects With Early Alzheimer’s Disease (LUCIDITY)

Status

Recruiting…

Study Description

The purpose of this study is to determine the safety and efficacy of TRx0237 8 mg/day and 16 mg/day in the treatment of subjects with early Alzheimer's Disease compared to placebo...

Sponsor

TauRx Therapeutics Ltd

Collaborator

TauRx Therapeutics Ltd

Learn More

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer’s Disease (Generation S1)

Status

Recruiting…

Study Description

The purpose of this study is to test whether two investigational drugs called CAD106 and CNP520, administered separately, can slow down the onset and progression of clinical symptoms associated with Alzheimer's disease (AD) in participants at the risk to develop clinical symptoms based on their age and genotype...

Sponsor

Novartis Pharmaceuticals

Collaborator

Banner Alzheimer's Institute, National Institute on Aging (NIA), Alzheimer's Association, Amgen

Learn More

A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer’s Disease (Mission AD1)

Status

Recruiting…

Study Description

The name of this trial is MissionAD1...

Sponsor

Eisai Co., Ltd.

Collaborator

Biogen

Learn More